Simmunome AI (Accelerator)

Company Description: Simmunome is an artificial intelligence-based contract research organization focused on predicting clinical trial outcomes using computational simulations. Using our machine-learning driven, biologically accurate disease models, a clinical researcher can determine the likelihood of success of a clinical program before stepping into the lab. We offer a different approach to leveraging AIML towards resolving biological complexity. At Simmunome, we understand that the complexity of “biological order” has to be replicated in order to accurately simulate outcomes. Our solution uses AI to accurately replicate biological complexity and through our robust validation process, provide a disease model that can be used to predict the outcome of targeting different parts of a biological system. With our approach, an R&D organization can de-risk their clinical programs by confirming whether the biological target they are going after will have any efficacy against the disease of interest. Our models can be used to optimize drug development pipelines in all the stages of clinical trial development as well as determine how to develop a clinical program to increase likelihood success. Altogether, a 4% increase in clinical trial success rate results in $30MM saved per drug. In total this would save organizations hundreds of millions and prevent years of opportunity cost.